Skip to main content

Table 4 CKD performance outcome measures for wave I and wave II practices

From: Leveraging practice-based research networks to accelerate implementation and diffusion of chronic kidney disease guidelines in primary care practices: a prospective cohort study

Performance measure

Wave I

Wave II

Pre-intervention period

Post-intervention period

pvalue*

Pre-intervention period

Post-intervention period

pvalue*

If eGFR <60

N = 374

N = 660

 ACE or ARB prescribed: n (%)

232 (63%)

255 (69%)

0.002

354 (55%)

407 (63%)

<0.001

 Taking NSAIDs: n (%)

25 (7%)

18 (5%)

0.10

51 (8%)

45 (7%)

0.44

 A1c testing performed: n (%)

288 (77%)

297 (79%)

0.25

492 (89%)

487 (88%)

0.65

 Urine microalbumin test performed: n (%)

158 (42%)

175 (47%)

0.16

NA

NA

NA

 LDL test performed: n (%)

309 (83%)

305 (82%)

0.75

NA

NA

NA

 A1c test results: Mean (SD)

7.1% (1.4)

7.2% (1.5)

0.78

7.4% (1.6)

7.3% (1.5)

0.07

 Systolic BP measure (mmHg): mean (SD)

132.5 (16.3)

132.8 (16.0)

0.72

132.0 (15.9)

131.4 (14.9)

0.39

 Diastolic BP measure (mmHg): mean (SD)

72.8 (9.1)

72.7 (9.0)

0.93

72.0 (9.4)

71.7 (8.5)

0.48

 LDL test result (mg/dl): mean (SD)

89.8 (36.6)

90.2 (32.8)

0.84

96.3 (38.1)

92.0 (34.5)

0.004

If eGFR <45

N = 138

N = 233

 Hemoglobin test performed: n (%)

84 (61%)

100 (72%)

0.02

NA

NA

NA

 Vitamin D testing (or supplement): n (%)

51 (37%)

83 (60%)

<0.001

87 (37%)

132 (57%)

<0.001

  1. SD standard deviation, NA not applicable because it was an annual recommendation and in wave II, the post-intervention period was only 9 months.
  2. *McNemar’s test was used to generate p values for categorical-scaled outcomes and the paired t test for continuous-scaled outcome measures.